|
| |
BiovailBiovail Corporation is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company's therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease (including Type II diabetes). Biovail drives business growth by commercializing these products both directly through its own sales and marketing divisions and/or through strategic partners. Biovail's core competency lies in the development and large-scale manufacturing of pharmaceutical products incorporating oral drug-delivery technologies. Biovail has a broad portfolio of proprietary drug-delivery technologies that represent the foundation upon which the Company's strategy is based.
Product candidates that meet a rigorous screening process are considered for addition to the Company's development pipeline. To this end, development efforts are currently ongoing for a number of pipeline products, including a once-daily formulation of carvedilol, novel formulations of bupropion and venlafaxine, separate combination products involving bupropion and tramadol, and a number of feasibility, or earlier-stage programs.
| Contact Details: |
| 7150 Mississauga Road |
| Mississauga |
| |
| L5N 8M5 |
| Canada |
| Tel: | 905.286.3000 |
| Fax: | 905.286.3050 |
| Email: | ir@biovail.com |
| WWW: | www.biovail.com/
|
|
Loading...
|
Recent Publications by Biovail: |  |
Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.
ABSTRACT: BACKGROUND: It is not known if there is a relationship between... | 25th December, 2008
| Biovail Corporation, Mississauga, Ontario, Canada.
| Ann Gen Psychiatry. 2008 Dec 23;7:27.
DOI Direct Link |
Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice.
ABSTRACT: BACKGROUND: It is known that following chronic dosing with... | 17th October, 2008
| Biovail Corporation, Mississauga, Ontario, Canada.
| Ann Gen Psychiatry. 2008 Oct 15;7:19.
DOI Direct Link |
Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride.
ABSTRACT: BACKGROUND: Bupropion HCl is a widely used antidepressant that... | 19th August, 2008
| Clinical Affairs, Biovail Corporation, Mississauga, Ontario, Canada.
| Ann Gen Psychiatry. 2008 Aug 18;7:11.
DOI Direct Link |
Determination of carryover and contamination for mass spectrometry-based chromatographic assays.
The Third American Association of Pharmaceutical Scientists/Food and Drug... | 6th February, 2008
| Biovail Contract Research,
| AAPS J. 2007 Nov 2;9(3):E353-60.
DOI Direct Link |
Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain.
BACKGROUND: Tramadol ER* is a once-daily oral analgesic for management of... | 15th December, 2007
| Clinical Development, Biovail Technologies, Ltd., Bridgewater, NJ, USA.
| Curr Med Res Opin. 2007 Oct;23(10):2531-42.
DOI Direct Link |
→View more Biovail research publications. |
Press Releases on Biovail:
|
 |
| Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research |
11th November, 2009 |
Pharma Market Research Conference |
PARSIPPANY, N.J., Nov. 11 /PRNewswire/ -- Pharma market research thought leaders are discovering new ways to take advantage of the tremendous developments and opportunities in the pharmaceutical
|
| Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook |
10th November, 2009 |
Reportlinker |
-- Profiles of key emerging drug delivery technologies and profiles of
leading companies, by type of technology
Who Should Buy This Report:
-- Companies interested in understanding
|
| Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech |
6th October, 2009 |
Reportlinker |
NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and
|
| Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents |
9th June, 2009 |
Decision Resources |
Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources
WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world
|
| Valeritas Announces Appointment of New CEO |
1st June, 2009 |
Valeritas, Inc. |
Former Johnson & Johnson Senior Executive Kristine Peterson to Take Helm
PARSIPPANY, N.J., June 1 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 868 times since April 2007, the link to the organisation's website has been followed 127 times Recent Search Terms used to find this page: biovail Email | newcrest biovail october 2008 | biovail company information | biovail april 2009 | biovail medicine mississauga | biovail medicine mississauga | . Search for more companies in Mississauga Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Biovail |
